ABSTRACT
In both humans with long-standing ulcerative colitis and mouse models of colitis-associated carcinogenesis (CAC), tumors develop predominantly in the distal part of the large intestine but the biological basis of this intriguing pathology remains unknown. Herein we report intrinsic differences in gene expression between proximal and distal colon in the mouse, which are augmented during dextran sodium sulfate (DSS)/azoxymethane (AOM)-induced CAC. Functional enrichment of differentially expressed genes identified discrete biological pathways operating in proximal vs distal intestine and revealed a cluster of genes involved in lipid metabolism to be associated with the disease-resistant proximal colon. Guided by this finding, we have further interrogated the expression and function of one of these genes, apolipoprotein A-I (ApoA-I), a major component of high-density lipoprotein. We show that ApoA-I is expressed at higher levels in the proximal compared with the distal part of the colon and its ablation in mice results in exaggerated DSS-induced colitis and disruption of epithelial architecture in larger areas of the large intestine. Conversely, treatment with an ApoA-I mimetic peptide ameliorated the phenotypic, histopathological and inflammatory manifestations of the disease. Genetic interference with ApoA-I levels in vivo impacted on the number, size and distribution of AOM/DSS-induced colon tumors. Mechanistically, ApoA-I was found to modulate signal transducer and activator of transcription 3 (STAT3) and nuclear factor-κB activation in response to the bacterial product lipopolysaccharide with concomitant impairment in the production of the pathogenic cytokine interleukin-6. Collectively, these data demonstrate a novel protective role for ApoA-I in colitis and CAC and unravel an unprecedented link between lipid metabolic processes and intestinal pathologies.
Subject(s)
Apolipoprotein A-I/metabolism , Carcinogenesis , Colitis/complications , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Animals , Apolipoprotein A-I/deficiency , Apolipoprotein A-I/genetics , Colitis/chemically induced , Colon/drug effects , Colon/metabolism , Colon/pathology , Colorectal Neoplasms/etiology , Colorectal Neoplasms/genetics , Dextran Sulfate/pharmacology , Disease Models, Animal , Female , Gene Expression Regulation, Neoplastic/drug effects , Gene Knockout Techniques , Mice , Mice, Inbred C57BLABSTRACT
Tumor Progression Locus 2 (TPL2) is widely recognized as a cytoplasmic mitogen-activated protein 3 kinase with a prominent role in the regulation of inflammatory and oncogenic signal transduction. Herein we report that TPL2 may also operate in the nucleus as a physical and functional partner of nucleophosmin (NPM/B23), a major nucleolar phosphoprotein with diverse cellular activities linked to malignancy. We demonstrate that TPL2 mediates the phosphorylation of a fraction of NPM at threonine 199, an event required for its proteasomal degradation and maintenance of steady-state NPM levels. Upon exposure to ultraviolet C, Tpl2 is required for the translocation of de-phosphorylated NPM from the nucleolus to the nucleoplasm. NPM is an endogenous inhibitor of HDM2:p53 interaction and knockdown of TPL2 was found to result in reduced binding of NPM to HDM2, with concomitant defects in p53 accumulation following genotoxic or ribosomal stress. These findings expand our understanding of the function of TPL2 as a negative regulator of carcinogenesis by defining a nuclear role for this kinase in the topological sequestration of NPM, linking p53 signaling to the generation of threonine 199-phosphorylated NPM.
Subject(s)
Active Transport, Cell Nucleus/radiation effects , MAP Kinase Kinase Kinases/metabolism , Nuclear Proteins/metabolism , Proto-Oncogene Proteins/metabolism , Tumor Suppressor Protein p53/metabolism , Animals , Cell Line , Cell Nucleus/metabolism , Cell Proliferation , Cell Transformation, Neoplastic , HEK293 Cells , Humans , MAP Kinase Kinase Kinases/genetics , MAP Kinase Kinase Kinases/radiation effects , Mice , Nucleolus Organizer Region/metabolism , Nucleophosmin , Phosphorylation , Protein Binding/genetics , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/radiation effects , Proto-Oncogene Proteins c-mdm2/metabolism , RNA Interference , RNA, Small Interfering , Signal Transduction/genetics , Ultraviolet RaysABSTRACT
CD40, a tumor necrosis factor receptor family member, is an emerging target for cancer therapy being best appreciated as an important regulator of the anti-tumor immune response. In this study, we report the development of a replication-defective recombinant adenovirus (RAd) vector expressing human CD40 ligand (RAd-hCD40L) and show that sustained engagement of the CD40 pathway in malignant cells results in direct anti-proliferative and pro-apoptotic effects. Thus, transduction of CD40-positive bladder, cervical and ovarian carcinoma cell lines with RAd-hCD40L potently inhibits their proliferation in vitro, whereas CD40-negative lines remain unresponsive. RAd-hCD40L is also found to be superior to recombinant CD40L in inducing carcinoma cell death and in amplifying the cytotoxic effects of the chemotherapeutic agents 5-fluorouracil, cis-platin and mitomycin C. Soluble CD40L is produced by RAd-hCD40L transduced carcinoma cells but unlike other soluble tumor necrosis factor family ligands, it does not interfere with the death-promoting activity of its membrane-bound form. In a mouse xenograft tumor model bearing a human bladder carcinoma, intratumoral delivery of RAd-hCD40L suppresses cancer growth. These findings highlight the potential of exploiting the CD40 pathway in carcinomas using CD40L gene transfer alone or in combination with other modalities for cancer therapy. Our results have also broader implications in understanding the multifaceted anti-tumor activities of the CD40 pathway in carcinomas, which thus offer an attractive option for future clinical application.
Subject(s)
Adenoviridae/genetics , CD40 Ligand/genetics , CD40 Ligand/metabolism , CD40 Ligand/physiology , Carcinoma/therapy , Genetic Therapy/methods , Animals , Antineoplastic Agents/therapeutic use , Apoptosis/physiology , Cell Line, Tumor , Cell Proliferation/drug effects , Cisplatin/therapeutic use , Flow Cytometry , Fluorouracil/therapeutic use , Humans , Immunoblotting , Mice , Mice, Nude , Mitomycin/therapeutic use , Xenograft Model Antitumor AssaysABSTRACT
To characterize the cellular components responsible for the impaired granulopoiesis in chronic idiopathic neutropenia (CIN), we investigated the origin of the proapoptotic cytokine producing cells in the bone marrow (BM) microenvironment of CIN patients. We found that the interferon gamma (IFN gamma) and/or Fas-ligand expressing cells in patient BM mononuclear cells and long-term BM culture stroma cells were the CD3(+) T-lymphocytes but not the CD14(+) monocytes/macrophages. The percentage of activated T-lymphocytes was increased in patients' BM as indicated by the proportions of human leucocyte antigen (HLA)-DR(+), CD25(+), CD38(+), CD69(+) and Fas(+) cells within the CD3(+) fraction. Intracellular IFN gamma expression was higher in the BM than peripheral blood of the patients and was associated with increased BM T-lymphocyte numbers. In crossover experiments, patient CD3(+) T-lymphocytes conferred autologous and allogeneic haemopoietic progenitor cell colony inhibition. Patients' T-cell receptor repertoire and polymerase chain reaction analysis did not reveal any clonal T-lymphocyte expansion, suggesting the absence of a direct, antigen-driven recognition of CD34(+) myeloid progenitor cells by patient T-lymphocytes. We conclude that CIN patients have increased number of activated T-lymphocytes in the BM, probably in the setting of a localized polyclonal immune reaction and that these cells confer an inhibitory effect on myelopoiesis through myelosuppressive cytokines including Fas-ligand and IFN gamma.
Subject(s)
Neutropenia/immunology , T-Lymphocytes/immunology , Adolescent , Adult , Aged , Bone Marrow/pathology , Chronic Disease , Clone Cells , Fas Ligand Protein , Female , Humans , Immunohistochemistry , Interferon-gamma/metabolism , Lymphocyte Activation , Lymphocyte Subsets , Male , Membrane Glycoproteins/metabolism , Middle Aged , Neutropenia/pathologyABSTRACT
Nasopharyngeal carcinoma is closely associated with Epstein-Barr virus (EBV) infection. The EBV-encoded LMP1 has cell transformation property. It suppresses cellular senescence and enhances cell survival in various cell types. Many of the downstream events of LMP1 expression are mediated through its ability to activate NF-kappaB. In this study, we report a novel function of LMP1 to induce Id1 expression in nasopharyngeal epithelial cells (NP69) and human embryonal kidney cells (HEK293). The Id1 is a basic helix-loop-helix (bHLH) protein and a negative transcriptional regulator of p16(INK4a). Expression of Id1 facilitates cellular immortalization and stimulates cell proliferation. With the combination of both specific chemical inhibitors and genetic inhibitors of cell signaling, we showed that induction of Id1 by LMP1 was dependent on its NF-kappaB activation domain at the carboxy-terminal region, CTAR1 and CTAR2. Induction of Id1 by LMP1 may facilitate clonal expansion of premalignant nasopharyngeal epithelial cells infected with EBV and may promote their malignant transformation.
Subject(s)
Epithelial Cells/metabolism , Gene Expression Regulation, Viral , Herpesvirus 4, Human/physiology , Nasopharynx/cytology , Repressor Proteins , Transcription Factors/physiology , Viral Matrix Proteins/physiology , Carcinoma/epidemiology , Carcinoma/etiology , Carcinoma/virology , Clone Cells/pathology , Cyclin-Dependent Kinase Inhibitor p16/biosynthesis , Epithelial Cells/virology , Epstein-Barr Virus Infections/genetics , Genes, p16 , Hong Kong/epidemiology , Humans , Inhibitor of Differentiation Protein 1 , NF-kappa B/physiology , Nasopharyngeal Neoplasms/epidemiology , Nasopharyngeal Neoplasms/etiology , Nasopharyngeal Neoplasms/virology , Protein Structure, Tertiary , Sequence Deletion , Signal Transduction , Transcription Factors/biosynthesis , Transcription Factors/genetics , Transcription, Genetic , Viral Matrix Proteins/chemistryABSTRACT
BACKGROUND/AIMS: CD40, a member of the tumour necrosis factor (TNF) receptor family, is expressed on a variety of haematopoietic cells and is crucial in orchestrating both humoral and cellular immune responses. CD40 is also expressed on some carcinoma cells, where its function remains largely unknown. This study investigated the effects of CD40 ligation on ovarian carcinoma cell growth and apoptosis and on cytokine production, in addition to the role of the NF-kappa B and JNK signalling pathways. METHODS: CD40 expression was measured in epithelial ovarian carcinoma (EOC) biopsies by immunohistochemistry and in EOC cell lines by flow cytometry. To examine the effects of CD40 ligation on cell growth recombinant soluble CD40 ligand was used to stimulate EOC cell lines and growth was measured by MMT assays. Cytokine production was measured by enzyme linked immunosorbent assays interleukin 8 (IL-8) gene transcription was estimated by means of reverse transcription polymerase chain reaction. The integrity of the CD40 signalling pathway in those cell lines that did not produce cytokines in response to CD40 ligation was assessed by the detection of the transcription factor NF-kappa B by an electrophoretic mobility shift assay. To investigate the defect in the NF-kappa B pathway the phosphorylation status of I kappa B alpha was determined by an antibody specific to phosphorylated I kappa B alpha and dissociation of the I kappa B alpha-p65 complex was assessed by co-immunoprecipitation. RESULTS: CD40 is expressed in primary ovarian carcinoma biopsies and EOC cell lines. CD40 ligation resulted in growth inhibition in most of these carcinoma cell lines and was also found to promote apoptosis, with this last effect only being evident in early passage EOC cells. CD40 ligation also induced significant IL-6 and IL-8 production in most of the EOC cell lines examined and it was confirmed for IL-8 that this effect was regulated at the transcriptional level. NF-kappa B activation in response to CD40 ligation was found in three of the EOC cell lines and specific defects in the CD40 induced NF-kappa B pathway were identified in two cell lines. However, CD40 engagement induced JNK activation in all the EOC cell lines. CONCLUSIONS: These data suggest that the CD40 pathway is functional in ovarian carcinoma cells and highlight the need for further studies to provide insight into the role of CD40 in the carcinogenic process and the possible exploitation of this pathway for novel therapeutic approaches.
Subject(s)
CD40 Antigens/metabolism , CD40 Ligand/metabolism , Carcinoma/immunology , Ovarian Neoplasms/immunology , Antibodies, Monoclonal/pharmacology , Apoptosis , CD40 Ligand/analysis , CD40 Ligand/immunology , Carcinoma/pathology , Cell Division , Electrophoretic Mobility Shift Assay , Female , Flow Cytometry , Humans , Immunohistochemistry , Interleukin-6/analysis , Interleukin-8/analysis , JNK Mitogen-Activated Protein Kinases , Mitogen-Activated Protein Kinases/analysis , NF-kappa B/immunology , Ovarian Neoplasms/pathology , Tumor Cells, CulturedABSTRACT
Although ovarian tumours initially respond to chemotherapy, they gradually acquire drug resistance. The aims of this study were to identify how chemotherapeutic drugs with diverse cellular targets activate apoptotic pathways and to investigate the mechanism by which exposure to a combination of drugs plus death receptor ligands can increase tumour cell kill. The results show that drugs with distinct cellular targets differentially up-regulate TRAIL and TNF as well CD95L, but do not require interaction of these ligands with their receptor partners to induce cell death. Factors that were critical in drug-induced apoptosis were activation of caspases, with caspase-8 being activated by diverse drugs in a FADD-independent manner. Certain drugs also demonstrated some dependence on FADD in the induction of cell death. Caspase-9 was activated more selectively by chemotherapeutic agents. Combining ligation of death receptors with exposure to drugs increased tumour cell kill in both drug resistant cell lines and primary ovarian carcinoma cells, even though these cells were not sensitive to death receptor ligation alone. CD95L was more consistent at combining with drugs than TRAIL or TNF. Investigation of the mechanism by which a combination of drugs plus CD95 ligation can increase cell death showed that caspase-8 was activated in cells exposed to a combination of cisplatin and anti-CD95, but not in cells exposed to either agent alone.
Subject(s)
Adaptor Proteins, Signal Transducing , Antineoplastic Agents/pharmacology , Apoptosis/physiology , Carrier Proteins/metabolism , Caspases/metabolism , Ovarian Neoplasms/metabolism , Adenoviridae/genetics , Apoptosis Regulatory Proteins , Caspase 3 , Caspase 8 , Caspase 9 , Cisplatin/pharmacology , Drug Combinations , Drug Resistance, Neoplasm/physiology , Drug Synergism , Enzyme Activation/drug effects , Enzyme Activation/physiology , Fas Ligand Protein , Fas-Associated Death Domain Protein , Female , Humans , Membrane Glycoproteins/metabolism , Membrane Glycoproteins/pharmacology , Ovarian Neoplasms/pathology , TNF-Related Apoptosis-Inducing Ligand , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation/drug effects , Up-Regulation/physiologyABSTRACT
Fas-mediated mechanisms of apoptosis are thought to be involved in the bile duct loss that characterizes diseases such as primary biliary cirrhosis (PBC). We have previously shown that activation of CD40 on hepatocytes can amplify Fas-mediated apoptosis; in the present study, we investigated interactions between CD40 and Fas in biliary epithelial cells (BEC). We report that the bile ducts in PBC liver tissue frequently express increased levels of Fas, Fas ligand (FasL), and CD40 associated with apoptotic BEC. The portal mononuclear infiltrate contains CD40L+ve T cells and macrophages, thereby demonstrating a potential mechanism for CD40 engagement in vivo. Primary cultures of human BEC also expressed Fas, FasL, and CD40 but not CD40L protein or mRNA. Activation of CD40 on BEC using recombinant CD40L increased transcriptional expression of FasL and induced apoptosis, which was inhibited by neutralizing antibodies to either Fas or FasL. Thus, CD40-induced apoptosis of BEC is mediated through Fas/FasL. We then investigated the intracellular signals and transcription factors activated in BEC and found that NF-kappaB and AP-1 were both activated after CD40 ligation. Increased functional NF-kappaB was seen early after CD40 ligation, but returned to baseline levels after 4 h. In contrast, the rapid up-regulation of AP-1 was sustained over 24 h. This study provides further functional evidence of the ability of CD40 to induce Fas/FasL-dependent apoptosis of liver epithelial cells supporting the importance of cross-talk between tumor necrosis factor (TNF) receptor family members as an amplification step in apoptosis induction. Sustained activation of AP-1 in the absence of NF-kappaB signaling may be a critical factor in determining the outcome of CD40 engagement.
Subject(s)
Apoptosis/physiology , Bile Ducts, Intrahepatic/physiology , CD40 Antigens/metabolism , NF-kappa B/physiology , Transcription Factor AP-1/physiology , fas Receptor/physiology , Bile Ducts, Intrahepatic/chemistry , Bile Ducts, Intrahepatic/cytology , CD40 Antigens/genetics , CD40 Ligand/metabolism , CD40 Ligand/pharmacology , Cells, Cultured , Epithelial Cells/chemistry , Epithelial Cells/cytology , Epithelial Cells/physiology , Fas Ligand Protein , Fluorescent Antibody Technique , Gene Expression Regulation , Humans , Immunohistochemistry , In Situ Nick-End Labeling , Liver Cirrhosis, Biliary/metabolism , Liver Cirrhosis, Biliary/pathology , Liver Cirrhosis, Biliary/physiopathology , Macrophages/chemistry , Macrophages/pathology , Membrane Glycoproteins/analysis , Membrane Glycoproteins/genetics , NF-kappa B/drug effects , NF-kappa B/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Signal Transduction , T-Lymphocytes/chemistry , T-Lymphocytes/pathology , Time Factors , Transcription Factor AP-1/drug effects , Transcription Factor AP-1/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation , fas Receptor/analysisABSTRACT
The oncogenic Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) has structural features and functions reminiscent of a constitutively active TNF family receptor. LMP1 aggregates at the plasma membrane and initiates the activation of signalling pathways, such as NF- kappa B, the mitogen-activated protein kinases JNK and p38, the small GTPase Cdc42 and the JAK/STAT cascade. The constitutive engagement of these signals and the characteristic molecular interactions that regulate them provide the basis for the molecular explanation of the transforming properties of this key EBV protein.
Subject(s)
Cell Transformation, Viral , Herpesvirus 4, Human/metabolism , Signal Transduction , Viral Matrix Proteins/chemistry , Viral Matrix Proteins/metabolism , Amino Acid Sequence , Animals , Herpesvirus 4, Human/chemistry , Humans , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Protein BindingABSTRACT
Sequence variants of the Epstein-Barr virus (EBV)-encoded latent membrane protein-1 (LMP1) have been reported in association with EBV-linked malignancies but little is known about their effects on signalling pathways and phenotype. We have examined the ability of the nasopharyngeal carcinoma (NPC)-derived variant, CAO-LMP1 to activate the transcription factors NF-kappaB and AP-1 in epithelial cells. In this study, transient expression of CAO-LMP1 was found to activate higher levels of NF-kappaB and AP-1 than the prototype B95.8-LMP1 in human embryonic kidney (HEK) 293 cells and SV40-transformed keratinocytes (SVK). In addition, pulse-chase analysis revealed that CAO-LMP1 has a longer half-life than B95.8-LMP1. Chimera studies localised these phenomena to the transmembrane domains of CAO-LMP1, suggesting that this enhanced signalling capacity may be a consequence of its prolonged half-life. The ability of CAO-LMP1 to activate higher levels of NF-kappaB and AP-1 may contribute to its potent transforming properties.
Subject(s)
Cell Membrane/metabolism , Herpesvirus 4, Human , Mutation/genetics , Signal Transduction , Viral Matrix Proteins/chemistry , Viral Matrix Proteins/metabolism , Cell Line , Cell Transformation, Neoplastic , DNA/genetics , DNA/metabolism , Epithelial Cells , Genetic Variation/genetics , Half-Life , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/physiology , Humans , Keratinocytes , NF-kappa B/metabolism , Nasopharyngeal Neoplasms/virology , Protein Structure, Tertiary , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Transcription Factor AP-1/metabolism , Viral Matrix Proteins/geneticsABSTRACT
The association of Epstein-Barr virus (EBV) with various malignancies is well established but the pattern of EBV latent gene expression in these different tumours is variable, reflecting distinct aspects of the virus-cell interaction. These different forms of EBV latency are associated with phenotypic variation and highlight the influence of EBV latent proteins on cell growth and survival. The EBV latent proteins have distinct functions associated with the maintenance of EBV infection and the control of various signalling and transcriptional pathways that facilitate the proliferation and survival of infected cells. Understanding the function of these EBV latent proteins will not only provide insight into the mechanisms governing fundamental cell processes but will also identify targets for novel treatment.
Subject(s)
Genes, Viral , Herpesvirus 4, Human/genetics , Virus Latency/genetics , Cell Communication/physiology , Cell Division/physiology , Cell Survival/physiology , Cell Transformation, Viral/genetics , Gene Expression , Herpesviridae Infections/physiopathology , Humans , PhenotypeABSTRACT
CD40, a tumor necrosis factor (TNF) receptor (TNFR) family member, conveys signals regulating diverse cellular responses, ranging from proliferation and differentiation to growth suppression and cell death. The ability of CD40 to mediate apoptosis in carcinoma cells is intriguing given the fact that the CD40 cytoplasmic C terminus lacks a death domain homology with the cytotoxic members of the TNFR superfamily, such as Fas, TNFR1, and TNF-related apoptosis-inducing ligand (TRAIL) receptors. In this study, we have probed the mechanism by which CD40 transduces death signals. Using a trimeric recombinant soluble CD40 ligand to activate CD40, we have found that this phenomenon critically depends on the membrane proximal domain (amino acids 216 to 239) but not the TNFR-associated factor-interacting PXQXT motif in the CD40 cytoplasmic tail. CD40-mediated cytotoxicity is blocked by caspase inhibitors, such as zVAD-fmk and crmA, and involves activation of caspase 8 and caspase 3. Interestingly, CD40 ligation was found to induce functional Fas ligand, TRAIL (Apo-2L) and TNF in apoptosis-susceptible carcinoma cells and to up-regulate expression of Fas. These findings identify a novel proapoptotic mechanism which is induced by CD40 in carcinoma cells and depends on the endogenous production of cytotoxic cytokines and autocrine or paracrine induction of cell death.
Subject(s)
Apoptosis/physiology , CD40 Antigens/metabolism , Carcinoma/metabolism , Tumor Necrosis Factor-alpha/metabolism , Viral Proteins , Amino Acid Motifs , Apoptosis/drug effects , CD40 Antigens/genetics , CD40 Ligand , Carcinoma/pathology , Caspase 3 , Caspase 8 , Caspase 9 , Caspase Inhibitors , Caspases/metabolism , Cycloheximide/pharmacology , Cysteine Proteinase Inhibitors/pharmacology , Fas Ligand Protein , Female , Humans , Ligands , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , Membrane Glycoproteins/metabolism , Serpins/metabolism , Signal Transduction , Tumor Cells, Cultured , fas Receptor/metabolismABSTRACT
The contribution of Epstein-Barr virus (EBV) strain variation to the pathogenesis of virus-associated tumours remains unknown. Given the central role of LMP1 in EBV-induced transformation, much interest has focused on the influence of LMP1 sequence variation on the signaling pathways and multiple downstream phenotypic consequences of LMP1 expression. The identification of LMP1 variants with a common 10-amino-acid deletion and additional point mutations (typified by the CAO-LMP1 isolate) in EBV strains associated with nasopharyngeal carcinoma prompted us to examine the effect of stable prototype B95.8-LMP1 and CAO-LMP1 expression on the phenotype and differentiation of SCC12F human epithelial cells. Both forms of LMP1 were able to induce expression of the antiapoptotic A20 protein and provide protection from tumour necrosis factor-alpha-induced cytotoxicity. Although B95.8-LMP1 induced growth inhibition, expression of certain cell surface molecules (CD40, CD44, and CD54), and secretion of interleukin-6 and -8 in SCC12F cells, stable CAO-LMP1 expression failed to elicit these effects. Furthermore, B95. 8-LMP1, but not CAO-LMP1, induced alterations in cell morphology and blocked epithelial cell differentiation. Both B95.8-LMP1 and CAO-LMP1 induced similar levels of nuclear factor-kappaB activation, but the ability of CAO-LMP1 to activate the AP-1 pathway was relatively impaired. These data highlight significant functional differences between the prototype B95.8-LMP1 and the CAO-LMP1 variant when stably expressed in human epithelial cells and suggest that continued analysis of LMP1 variants will help to further dissect the signaling pathways activated by LMP1 as well as provide insights into the contribution of LMP1 sequence variation to the pathogenesis of EBV-associated tumours.
Subject(s)
Epithelial Cells/metabolism , Herpesvirus 4, Human/chemistry , Nasopharyngeal Neoplasms/chemistry , Nasopharyngeal Neoplasms/virology , Proteins , Viral Matrix Proteins/metabolism , Antigens, CD/biosynthesis , Cell Differentiation , Cell Division , Cell Line , Cell Membrane/metabolism , Cell Size , Cell Survival/drug effects , DNA/genetics , DNA/metabolism , DNA-Binding Proteins , Epithelial Cells/cytology , Epithelial Cells/drug effects , Epithelial Cells/virology , Genetic Variation/genetics , Humans , Interleukins/biosynthesis , Interleukins/metabolism , Intracellular Signaling Peptides and Proteins , Mutation/genetics , NF-kappa B/metabolism , Nasopharyngeal Neoplasms/metabolism , Nuclear Proteins , Protein Biosynthesis , Signal Transduction , Transcription Factor AP-1/metabolism , Transfection , Tumor Necrosis Factor alpha-Induced Protein 3 , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation , Viral Matrix Proteins/geneticsABSTRACT
Cdc42, a Rho-family GTPase, has been implicated in several signal transduction pathways, including organization of the actin cytoskeleton, activation of the c-Jun N-terminal MAP kinase (JNK) and stimulation of the nuclear transcription factor kappa B (NF(kappa)B). We report here that exposure of fibroblasts to the inflammatory cytokines tumor necrosis factor (alpha) (TNF(alpha)) and interleukin-1 (IL-1) triggers the activation of Cdc42 leading first to filopodia formation and subsequently to Rac and Rho activation. Inhibition of Cdc42 completely suppresses cytokine-induced actin polymerization, but not activation of JNK or NF(kappa)B. The latent membrane protein 1 of Epstein-Barr virus, LMP1, is thought to mimic constitutively activated TNF family receptors. When expressed in fibroblasts, LMP1 stimulates Cdc42-dependent filopodia formation as well as JNK and NF(kappa)B activation. Using LMP1 mutants, we show that activation of Cdc42 and JNK/NF(kappa)B occur through distinct pathways and that Cdc42 activation is independent of LMP1's interaction with TRADD and TRAF proteins.
Subject(s)
Cytoskeleton/drug effects , Interleukin-1/pharmacology , Tumor Necrosis Factor Receptor-Associated Peptides and Proteins , Tumor Necrosis Factor-alpha/pharmacology , Viral Matrix Proteins/pharmacology , cdc42 GTP-Binding Protein/metabolism , 3T3 Cells/drug effects , Actin Cytoskeleton/metabolism , Actins/metabolism , Animals , Bacterial Proteins/metabolism , Becaplermin , Biopolymers , Culture Media, Serum-Free/pharmacology , Cytoskeleton/ultrastructure , Enzyme Activation/drug effects , Fibroblasts/drug effects , Herpesvirus 4, Human/physiology , Inflammation , JNK Mitogen-Activated Protein Kinases , Mice , Microinjections , Microscopy, Fluorescence , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Platelet-Derived Growth Factor/pharmacology , Proteins/metabolism , Proto-Oncogene Proteins c-sis , Pseudopodia/drug effects , Recombinant Proteins/pharmacology , Signal Transduction , TNF Receptor-Associated Death Domain Protein , TNF Receptor-Associated Factor 1 , cdc42 GTP-Binding Protein/antagonists & inhibitorsABSTRACT
The Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) is a pleiotropic protein the activities of which include effects on gene expression and cell transformation, growth, and death. LMP1 has been shown to induce nuclear factor (NF)-kappaB and c-Jun NH2-terminal kinase/AP-1 activities in target cells, and in this study we demonstrate that LMP1 also engages the p38 mitogen-activated protein kinase cascade, leading to activation of the transcription factor ATF2. Mutational analysis of the LMP1 cytoplasmic COOH terminus revealed that p38 activation occurs from both the tumor necrosis factor receptor-associated factor (TRAF)-interacting, membrane-proximal COOH-terminal activating region (CTAR)1 domain (amino acids 186-231) and the extreme tumor necrosis factor receptor-associated death domain (TRADD) binding CTAR2 region (amino acids 351-386). Because LMP1 also engages signaling on the NF-kappaB axis through CTAR1 and CTAR2, we have examined whether these two pathways are overlapping or independent. We have found that inhibition of p38 by the highly specific inhibitor SB203580 did not affect NF-kappaB binding activity. Conversely, although the metabolic inhibitor D609 blocked NF-kappaB activation, it did not impair the ability of LMP1 to signal on the p38 axis, suggesting that these two LMP1-mediated pathways are primarily independent. Divergence of signals must, however, occur downstream of TRAF2 as a dominant negative TRAF2 mutant that blocks LMP1-induced NF-kappaB activation also inhibited p38 signaling. In addition, we have found that p38 inhibition significantly impaired LMP1-mediated interleukin-6 and -8 expression. Thus, p38 may play a significant cooperative role in regulating at least some of the pleiotropic activities of LMP1.
Subject(s)
Antigens, Viral/metabolism , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Interleukin-6/biosynthesis , Interleukin-8/biosynthesis , Mitogen-Activated Protein Kinases , Viral Matrix Proteins/metabolism , Activating Transcription Factor 2 , Animals , Binding Sites , Cell Line , Cyclic AMP Response Element-Binding Protein/metabolism , Ecdysterone/analogs & derivatives , Ecdysterone/pharmacology , Enzyme Activation , Enzyme-Linked Immunosorbent Assay , Herpesvirus 4, Human , Humans , Proteins/metabolism , Rats , TNF Receptor-Associated Factor 2 , Transcription Factors/metabolism , p38 Mitogen-Activated Protein KinasesABSTRACT
CD40 is present on B cells, monocytes, dendritic cells, and endothelial cells, as well as a variety of neoplastic cell types, including carcinomas. CD40 stimulation by an antibody has previously been demonstrated to induce activation-induced cell death in aggressive histology human B-cell lymphoma cell lines. Therefore, we wanted to assess the effects of a recombinant soluble human CD40 ligand (srhCD40L) on human breast carcinoma cell lines. Human breast carcinoma cell lines were examined for CD40 expression by flow cytometry. CD40 expression could be detected on several human breast cancer cell lines and this could be augmented with interferon-gamma. The cell lines were then incubated with a srhCD40L to assess effects on in vitro growth. srhCD40L significantly inhibited the proliferation of the CD40(+) human breast cancer cell lines. This inhibition could also be augmented with interferon-gamma. Viability was also affected and this was shown to be due to increased apoptosis of the cell lines in response to the ligand. Treatment of tumor-bearing mice was then performed to assess the in vivo efficacy of the ligand. Treatment of tumor-bearing SCID mice with the ligand resulted in significant increases in survival. Thus, CD40 stimulation by its ligand directly inhibits human breast carcinoma cells in vitro and in vivo. These results suggest that srhCD40L may be of clinical use to inhibit human breast carcinoma growth.
Subject(s)
Breast Neoplasms/pathology , CD40 Antigens/physiology , Membrane Glycoproteins/therapeutic use , Animals , Antigens, CD/genetics , Antigens, CD/physiology , Apoptosis , Breast Neoplasms/immunology , CD40 Antigens/genetics , CD40 Ligand , Carcinoma, Ductal, Breast/pathology , Cell Division , Cell Survival , Female , Flow Cytometry , Humans , Ligands , Membrane Glycoproteins/toxicity , Mice , Mice, SCID , Recombinant Proteins/therapeutic use , Recombinant Proteins/toxicity , Transplantation, Heterologous , Tumor Cells, CulturedABSTRACT
The transforming Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) activates signalling on the NF-kappaB axis through two distinct domains in its cytoplasmic C terminus, namely, CTAR1 (amino acids [aa] 187 to 231) and CTAR2 (aa 351 to 386). The ability of CTAR1 to activate NF-kappaB appears to be attributable to the direct interaction of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2), while recent work indicates that CTAR2-induced NF-kappaB is mediated through its association with TNF receptor-associated death domain (TRADD). LMP1 expression also results in activation of the c-Jun N-terminal kinase (JNK) (also known as stress-activated protein kinase) cascade, an effect which is mediated exclusively through CTAR2 and can be dissociated from NF-kappaB induction. The organization and signalling components involved in LMP1-induced JNK activation are not known. In this study we have dissected the extreme C terminus of LMP1 and have identified the last 8 aa of the protein (aa 378 to 386) as being important for JNK signalling. Using a series of fine mutants in which single amino acids between codons 379 and 386 were changed to glycine, we have found that mutations of Pro379, Glu381, Ser383, or Tyr384 diminish the ability of LMP1 CTAR2 to engage JNK signalling. Interestingly, this region was also found to be essential for CTAR2-mediated NF-kappaB induction and coincides with the LMP1 amino acid sequences shown to bind TRADD. Furthermore, we have found that LMP1-mediated JNK activation is synergistically augmented by low levels of TRADD expression, suggesting that this adapter protein is critical for LMP1 signalling. TRAF2 is known to associate with TRADD, and expression of a dominant-negative N-terminal deletion TRAF2 mutant was found to partially inhibit LMP1-induced JNK activation in 293 cells. In addition, the TRAF2-interacting protein A20 blocked both LMP1-induced JNK and NF-kappaB activation, further implicating TRAF2 in these phenomena. While expression of a kinase-inactive mutated NF-kappaB-inducing kinase (NIK), a mitogen-activated protein kinase kinase kinase which also associates with TRAF2, impaired LMP1 signalling on the NF-kappaB axis, it did not inhibit LMP1-induced JNK activation, suggesting that these two pathways may bifurcate at the level of TRAF2. These data further define a role for TRADD and TRAF2 in JNK activation and confirm that LMP1 utilizes signalling mechanisms used by the TNF receptor/CD40 family to elicit its pleiotropic activities.
Subject(s)
Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Herpesvirus 4, Human/metabolism , Mitogen-Activated Protein Kinases , Proteins/metabolism , Signal Transduction , Viral Matrix Proteins/metabolism , Amino Acids , Animals , Binding Sites , COS Cells , Calcium-Calmodulin-Dependent Protein Kinases/genetics , Cell Line, Transformed , DNA-Binding Proteins , Enzyme Activation , Herpesvirus 4, Human/genetics , Humans , Intracellular Signaling Peptides and Proteins , JNK Mitogen-Activated Protein Kinases , NF-kappa B/metabolism , Nuclear Proteins , Protein Serine-Threonine Kinases/metabolism , Proteins/genetics , TNF Receptor-Associated Factor 1 , TNF Receptor-Associated Factor 2 , Tumor Necrosis Factor alpha-Induced Protein 3 , Viral Matrix Proteins/genetics , NF-kappaB-Inducing KinaseABSTRACT
We propose that a novel mechanism of hepatocyte apoptosis, involving a cooperative interaction between CD40 and Fas, is involved in the hepatocyte loss of chronic liver allograft rejection. We detected increased hepatocyte expression of Fas, Fas ligand (FasL), and CD40 associated with dropout of centrilobular (acinar zone 3) hepatocytes in chronic allograft rejection. Expression of CD40 ligand (CD40L) was also increased but was largely restricted to CD68(+) macrophages. A functional role for CD40 and Fas in hepatocyte apoptosis was demonstrated in vitro using primary human hepatocytes and the HepG2 cell line in both of which apoptosis was induced, not only by cross-linking Fas directly but also via CD40 activation. Our data suggest that CD40 activation induces apoptosis via Fas because (a) ligation of CD40 upregulated hepatocyte FasL expression, and (b) apoptosis induced via activation of CD40 was prevented by a neutralizing monoclonal antibody to FasL. Thus, CD40 engagement triggers apoptosis of human hepatocytes and might amplify Fas-dependent hepatocyte apoptosis in chronic rejection and other inflammatory liver diseases in which Fas-mediated apoptosis is involved.
Subject(s)
Apoptosis/physiology , CD40 Antigens/metabolism , Graft Rejection/immunology , Liver/immunology , Membrane Glycoproteins/metabolism , Transplantation, Homologous/immunology , Antibodies, Monoclonal/pharmacology , Cell Line , Fas Ligand Protein , Flow Cytometry , Humans , Immunohistochemistry , Inflammation/immunology , Liver/pathology , Microscopy, FluorescenceABSTRACT
The widespread expression of CD40 in normal epithelial cells and carcinoma cells suggests that this receptor has important, additional influences beyond that of regulating immune responses. Here, Lawrence Young and colleagues discuss the effect of CD40 ligation on epithelial cells and consider the role of this pathway in the pathogenesis and treatment of carcinomas.